Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Stock data | 2024 | Change |
---|---|---|
Price | $0.05311504225745278 | N/A |
Market Cap | $41.54M | N/A |
Shares Outstanding | 782.06M | N/A |
Employees | 27.00 | N/A |